Treatment involves early Alzheimer’s disease and will be potentially used across Great Britain
News
Vital patent for AlzeCure Alzheimer’s drug
ACD856 is the leading candidate therapy on the company’s NeuroRestore platform
AstraZeneca’s dapagliflozin recommended by NICE
Treatment concerns up to 150,000 patients in England with chronic heart failure
NICE nod for Genedrive’s CYP2C19 candidate
Screening patients to assess their clopidogrel resistance status will allow for alternative treatments
Debiopharm commences pivotal glioblastoma therapy study
The therapy is a brain-penetrant used in various combinations in patients with progressive glioblastoma
NICE recommendation for AbbVie’s Rinvoq
The approved drug has been developed to treat patients with moderate to severe Crohn’s disease
Pharmanovia and Closed Loop Medicine in precision medicine partnership
Dosing optimisation technology will be incorporated alongside anti-hypertensive drugs
FIND and VIA Global Health expand access to diagnostics
Partnership will provide a healthcare boost across in low and middle-income countries
Robotic platform R-One+ launched by Robocath
Solution allows a cardiologist to perform coronary angioplasties using an integrated control command unit
Approval provided for Angelini’s cenobamate
Treatment will now be used across Ireland among adults with focal onset seizures with epilepsy
NHS patients gain access to Gilead’s Hepcludex
NICE’s decision will result in eligible patients using a treatment that slows or halts aspects of the illness
Positive data for Acesion’s atrial fibrillation candidates
The company intends to advance AF drugs that address current risk concerns with existing therapies
Integrated pathology unit to focus on novel technology
The first unit of its kind in England will identify biomarkers and diagnose cancer much faster
NHS stats prompt NHS Confederation response
Confederation responds to generally positive statistics, including cancer backlog drop
European Commission green lights Servier’s Tibsovo
Treatment concerns patients with IDH1-mutated acute myeloid leukaemia and IDH1-mutated cholangiocarcinoma
